Amino acid variation at VP1-145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice

Journal of Virology

Volumn 92, Issue 15, 2018, Pages

  Kobayashi, Kyousuke ^a   Sudaka, Yui ^a   Takashino, Ayako ^a   Imura, Ayumi ^a   Fujii, Ken ^a   Koike, Satoshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Animal models; Enterovirus; Pathogenesis; Receptors

Indexed keywords

GLUTAMIC ACID; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR B2; UNCLASSIFIED DRUG; CAPSID PROTEIN; GLYCINE; HEPARAN SULFATE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; SCARB2 PROTEIN, HUMAN; SCAVENGER RECEPTOR;

AMINO ACID ANALYSIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROVIRUS A71; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUCKLING ANIMAL; TRANSGENIC MOUSE; VASCULAR ENDOTHELIAL CELL; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; AMINO ACID SUBSTITUTION; ANIMAL; CELL LINE; CENTRAL NERVOUS SYSTEM; CYTOLOGY; DISEASE MODEL; ENDOTHELIUM CELL; ENTEROVIRUS A; ENTEROVIRUS INFECTION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRUS LOAD;

AMINO ACID SUBSTITUTION; ANIMALS; CAPSID PROTEINS; CELL LINE; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; GLYCINE; HEPARITIN SULFATE; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MUTATION; RECEPTORS, SCAVENGER; VIRAL LOAD; VIRUS ATTACHMENT;

EID: 85050148417     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00681-18     Document Type: Article

References (50)

1. Pallansch M, Oberste MS, Whitton JL. 2013. Enteroviruses: polioviruses, coxackieviruses, echoviruses, and newer enteroviruses, p 490-530. In Knipe D, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA
2. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, Jegathesan M, Anderson LJ, for the Outbreak Study Group. 2000. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis 31:678-683. https://doi.org/10.1086/314032
3. Khanh TH, Sabanathan S, Thanh TT, Thoa le PK, Thuong TC, Hang V, Farrar J, Hien TT, Chau N, van Doorn HR. 2012. Enterovirus 71-associated hand, foot, and mouth disease, southern Vietnam, 2011. Emerg Infect Dis 18:2002-2005. https://doi.org/10.3201/eid1812.120929
4. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341:929-935
5. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. 2010. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 7:94. https://doi.org/10.1186/1743-422X-7-94
6. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. 2007. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 120:e244-252. https://doi.org/ 10.1542/peds.2006-3331
7. Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 82:1787-1797. https://doi.org/10.1128/JVI.01798-07
8. Huang SW, Wang YF, Yu CK, Su IJ, Wang JR. 2012. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422:132-143. https://doi.org/10.1016/j.virol.2011.10.015
9. Zaini Z, McMinn P. 2012. A single mutation in capsid protein VP1 (Q145E) of a genogroup C4 strain of human enterovirus 71 generates a mousevirulent phenotype. J Gen Virol 93:1935-1940. https://doi.org/10.1099/ vir.0.043893-0
10. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, Su IJ, Wang JR, Yeh TM, Chen SH, Yu CK. 2004. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78:7916-7924. https://doi.org/10.1128/JVI.78.15.7916-7924.2004
11. Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. 2008. The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol 89:1622-1632. https://doi.org/10.1099/vir.0.83676-0
12. Liu Y, Fu C, Wu S, Chen X, Shi Y, Zhou B, Zhang L, Zhang F, Wang Z, Zhang Y, Fan C, Han S, Yin J, Peng B, Liu W, He X. 2014. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Genes 48:260-272. https://doi.org/10.1007/ s11262-014-1035-2
13. Zhang B, Wu X, Huang K, Li L, Zheng L, Wan C, He ML, Zhao W. 2014. The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection. BMC Infect Dis 14:243. https://doi.org/10.1186/1471-2334-14-243
14. Li R, Zou Q, Chen L, Zhang H, Wang Y. 2011. Molecular analysis of virulent determinants of enterovirus 71. PLoS One 6:e26237. https://doi.org/10.1371/journal.pone.0026237
15. Chang SC, Li WC, Chen GW, Tsao KC, Huang CG, Huang YC, Chiu CH, Kuo CY, Tsai KN, Shih SR, Lin TY. 2012. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J Med Virol 84:931-939. https://doi.org/10.1002/jmv.23287
16. Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, Sanjoh K, Sakamoto M, Hongo S, Murayama S, Hayasaka K. 2005. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 43: 6171-6175. https://doi.org/10.1128/JCM.43.12.6171-6175.2005
17. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798-801. https://doi.org/10.1038/nm.1992
18. Yamayoshi S, Ohka S, Fujii K, Koike S. 2013. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87:3335-3347. https://doi.org/10.1128/JVI.02070-12
19. Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. 2012. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 86:5686-5696. https://doi.org/10.1128/JVI.00020-12
20. He Y, Ong KC, Gao Z, Zhao X, Anderson VM, McNutt MA, Wong KT, Lu M. 2014. Tonsillar crypt epithelium is an important extra-central nervous system site for viral replication in EV71 encephalomyelitis. Am J Pathol 184:714-720. https://doi.org/10.1016/j.ajpath.2013.11.009
21. Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, Koike S. 2013. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A 110: 14753-14758. https://doi.org/10.1073/pnas.1217563110
22. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794-797. https://doi.org/10.1038/nm.1961
23. Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611-620. https://doi.org/10.1128/JVI.02226-12
24. Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 85:11809-11820. https://doi.org/10.1128/JVI.00297-11
25. Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. 2012. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol 12:162. https://doi.org/10.1186/1471-2180-12-162
26. Su PY, Wang YF, Huang SW, Lo YC, Wang YH, Wu SR, Shieh DB, Chen SH, Wang JR, Lai MD, Chang CF. 2015. Cell surface nucleolin facilitates enterovirus 71 binding and infection. J Virol 89:4527-4538. https://doi.org/10.1128/JVI.03498-14
27. Du N, Cong H, Tian H, Zhang H, Zhang W, Song L, Tien P. 2014. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol 88:5816-5833. https://doi.org/10.1128/JVI.03826-13
28. Tan CW, Sam IC, Lee VS, Wong HV, Chan YF. 2017. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501:79-87. https://doi.org/10.1016/j.virol.2016.11.009
29. Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 2013. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9:e1003511. https://doi.org/10.1371/journal.ppat.1003511
30. Sarrazin S, Lamanna WC, Esko JD. 2011. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3:a004952. https://doi.org/10.1101/ cshperspect.a004952
31. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. 2005. The alpha/ beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79:4460-4469. https://doi.org/10.1128/JVI.79.7.4460-4469.2005
32. Kataoka C, Suzuki T, Kotani O, Iwata-Yoshikawa N, Nagata N, Ami Y, Wakita T, Nishimura Y, Shimizu H. 2015. The role of VP1 amino acid residue 145 of enterovirus 71 in viral fitness and pathogenesis in a cynomolgus monkey model. PLoS Pathog 11:e1005033. https://doi.org/ 10.1371/journal.ppat.1005033
33. Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, Iwata-Yoshikawa N, Konani O, Ami Y, Shimizu H, Nagata N, Mizuta K, Matsuzaki Y, Koike S. 2018. VP1 amino acid residue 145 of enterovirus 71 is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection. J Virol 92:e00682-18. https://doi.org/10.1128/JVI.00682-18
34. Lee E, Lobigs M. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76:4901-4911. https://doi.org/ 10.1128/JVI.76.10.4901-4911.2002
35. Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 78:8271-8280. https://doi.org/10.1128/JVI.78.15.8271-8280.2004
36. Lee E, Wright PJ, Davidson A, Lobigs M. 2006. Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87:2791-2801. https://doi.org/10.1099/vir.0.82164-0
37. Anez G, Men R, Eckels KH, Lai CJ. 2009. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol 83:10384-10394. https://doi.org/10.1128/JVI.01083-09
38. Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ. 2008. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J Virol 82:12510-12519. https://doi.org/ 10.1128/JVI.00458-08
39. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75:5627-5637. https://doi.org/10.1128/JVI.75.12.5627-5637.2001
40. Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 72:7357-7366
41. Ryman KD, Klimstra WB, Johnston RE. 2004. Attenuation of Sindbis virus variants incorporating uncleaved PE2 glycoprotein is correlated with attachment to cell-surface heparan sulfate. Virology 322:1-12. https:// doi.org/10.1016/j.virol.2004.01.003
42. Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. 2014. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719. https:// doi.org/10.1371/journal.pntd.0002719
43. Ashbrook AW, Burrack KS, Silva LA, Montgomery SA, Heise MT, Morrison TE, Dermody TS. 2014. Residue 82 of the chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice. J Virol 88:12180-12192. https://doi.org/10.1128/JVI.01672-14
44. Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. 2014. A single-amino-acid polymorphism in chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol 88:2385-2397. https://doi.org/10.1128/JVI.03116-13
45. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. https://doi.org/10.1006/viro.2000.0546
46. Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71:5115-5123
47. Wang Y, Pfeiffer JK. 2016. Emergence of a large-plaque variant in mice Infected with coxsackievirus B3. mBio 7:e00119. https://doi.org/10.1128/ mBio.00119-16
48. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281-2308. https://doi.org/10.1038/nprot.2013.143
49. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol 162:480-483. https://doi.org/10.1007/BF01863914
50. Jonsson N, Gullberg M, Lindberg AM. 2009. Real-time polymerase chain reaction as a rapid and efficient alternative to estimation of picornavirus titers by tissue culture infectious dose 50% or plaque forming units. Microbiol Immunol 53:149-154